Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa.

Mukinda FK, Theron D, van der Spuy GD, Jacobson KR, Roscher M, Streicher EM, Musekiwa A, Coetzee GJ, Victor TC, Marais BJ, Nachega JB, Warren RM, Schaaf HS.

Int J Tuberc Lung Dis. 2012 Feb;16(2):196-202. doi: 10.5588/ijtld.11.0116.

2.

Rifampicin-monoresistant Mycobacterium tuberculosis disease among children in Cape Town, South Africa.

Dramowski A, Morsheimer MM, Jordaan AM, Victor TC, Donald PR, Schaaf HS.

Int J Tuberc Lung Dis. 2012 Jan;16(1):76-81. doi: 10.5588/ijtld.11.0360.

3.

Rifampicin mono-resistance in Mycobacterium tuberculosis in KwaZulu-Natal, South Africa: a significant phenomenon in a high prevalence TB-HIV region.

Coovadia YM, Mahomed S, Pillay M, Werner L, Mlisana K.

PLoS One. 2013 Nov 6;8(11):e77712. doi: 10.1371/journal.pone.0077712. eCollection 2013.

4.

Rifampin monoresistant tuberculosis and HIV comorbidity in California, 1993-2008: a retrospective cohort study.

Prach LM, Pascopella L, Barry PM, Flood J, Porco TC, Hopewell PC, Metcalfe JZ.

AIDS. 2013 Oct 23;27(16):2615-22. doi: 10.1097/01.aids.0000432445.07437.07.

5.

The evolving epidemic of drug-resistant tuberculosis among children in Cape Town, South Africa.

Seddon JA, Hesseling AC, Marais BJ, Jordaan A, Victor T, Schaaf HS.

Int J Tuberc Lung Dis. 2012 Jul;16(7):928-33. doi: 10.5588/ijtld.11.0679. Epub 2012 May 8.

PMID:
22583610
6.

Risk factors for rifampin-monoresistant tuberculosis: A case-control study.

Sandman L, Schluger NW, Davidow AL, Bonk S.

Am J Respir Crit Care Med. 1999 Feb;159(2):468-72.

PMID:
9927359
7.

Microbiological investigation for tuberculosis among HIV-infected children in Soweto, South Africa.

Fairlie L, Muchiri E, Beylis CN, Meyers T, Moultrie H.

Int J Tuberc Lung Dis. 2014 Jun;18(6):676-81. doi: 10.5588/ijtld.13.0839.

PMID:
24903938
8.

Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.

Scott LE, McCarthy K, Gous N, Nduna M, Van Rie A, Sanne I, Venter WF, Duse A, Stevens W.

PLoS Med. 2011 Jul;8(7):e1001061. doi: 10.1371/journal.pmed.1001061. Epub 2011 Jul 26.

9.

Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial.

Cox HS, Mbhele S, Mohess N, Whitelaw A, Muller O, Zemanay W, Little F, Azevedo V, Simpson J, Boehme CC, Nicol MP.

PLoS Med. 2014 Nov 25;11(11):e1001760. doi: 10.1371/journal.pmed.1001760. eCollection 2014 Nov.

10.

Culture-confirmed childhood tuberculosis in Cape Town, South Africa: a review of 596 cases.

Schaaf HS, Marais BJ, Whitelaw A, Hesseling AC, Eley B, Hussey GD, Donald PR.

BMC Infect Dis. 2007 Nov 29;7:140.

11.

Diagnostic accuracy and usefulness of the Genotype MTBDRplus assay in diagnosing multidrug-resistant tuberculosis in Cameroon? a cross-sectional study.

Abanda NN, Djieugoué JY, Lim E, Pefura-Yone EW, Mbacham WF, Vernet G, Penlap VM, Eyangoh SI, Taylor DW, Leke RGF.

BMC Infect Dis. 2017 May 31;17(1):379. doi: 10.1186/s12879-017-2489-3.

12.

Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009.

Gegia M, Cohen T, Kalandadze I, Vashakidze L, Furin J.

Int J Tuberc Lung Dis. 2012 Jun;16(6):812-6. doi: 10.5588/ijtld.11.0637. Epub 2012 Apr 9.

13.

Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N.

Cochrane Database Syst Rev. 2014 Jan 21;(1):CD009593. doi: 10.1002/14651858.CD009593.pub3. Review.

14.

Spoligotype-based comparative population structure analysis of multidrug-resistant and isoniazid-monoresistant Mycobacterium tuberculosis complex clinical isolates in Poland.

Jagielski T, Augustynowicz-Kopec E, Zozio T, Rastogi N, Zwolska Z.

J Clin Microbiol. 2010 Nov;48(11):3899-909. doi: 10.1128/JCM.00572-10. Epub 2010 Sep 1.

15.

Rapid genotypic assays to identify drug-resistant Mycobacterium tuberculosis in South Africa.

Evans J, Stead MC, Nicol MP, Segal H.

J Antimicrob Chemother. 2009 Jan;63(1):11-6. doi: 10.1093/jac/dkn433. Epub 2008 Oct 21.

PMID:
18940875
16.

Evaluation of a rapid screening test for rifampicin resistance in re-treatment tuberculosis patients in the Eastern Cape.

Albert H, Trollip AP, Seaman T, Abrahams C, Mole RJ, Jordaan A, Victor T, Hoosain E.

S Afr Med J. 2007 Sep;97(9):858-63.

17.

M. tuberculosis genotypic diversity and drug susceptibility pattern in HIV-infected and non-HIV-infected patients in northern Tanzania.

Kibiki GS, Mulder B, Dolmans WM, de Beer JL, Boeree M, Sam N, van Soolingen D, Sola C, van der Zanden AG.

BMC Microbiol. 2007 May 31;7:51.

18.

Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, Pai M, Dendukuri N.

Cochrane Database Syst Rev. 2013 Jan 31;(1):CD009593. doi: 10.1002/14651858.CD009593.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;(1):CD009593.

19.

High prevelance of rifampin-monoresistant tuberculosis: a retrospective analysis among Iranian pulmonary tuberculosis patients.

Velayati AA, Farnia P, Mozafari M, Sheikholeslami MF, Karahrudi MA, Tabarsi P, Hoffner S.

Am J Trop Med Hyg. 2014 Jan;90(1):99-105. doi: 10.4269/ajtmh.13-0057. Epub 2013 Nov 4.

20.

Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study.

Lawn SD, Brooks SV, Kranzer K, Nicol MP, Whitelaw A, Vogt M, Bekker LG, Wood R.

PLoS Med. 2011 Jul;8(7):e1001067. doi: 10.1371/journal.pmed.1001067. Epub 2011 Jul 26.

Supplemental Content

Support Center